The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

The neuroendocrine carcinoma market is experiencing steady growth driven by rising disease prevalence and improved diagnostic capabilities. Advancements in targeted therapies and immunotherapies ...

Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs' or the 'Company,' Stock Code: 9887.HK) announced on March 6, 2026 that the ...

Independently developed by Junshi Biosciences, JS001sc injection is a subcutaneous injection based on the marketed product toripalimab injection (code: JS001) that is expected to enhance convenience ...

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) support the ...

Novo Nordisk (NVO) stock is in focus as FDA declines a cancer drug approval for Incyte (INCY) and MacroGenics (MGNX) due to ...

Researchers from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research ...

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Vegetarian diet is linked to lower risks of pancreatic, kidney, breast, prostate cancers, and multiple myeloma, but higher esophageal cancer risk.

"We are very pleased to welcome Bryan to Zenith's board of directors," said Donald McCaffrey, Chairman and CEO. "Bryan has an excellent reputation for prudent advice and creative insights, and we look ...